U.S. FDA bans more products from Ranbaxy

U.S. FDA bans more products from Ranbaxy

The U. S. Food & Drug Administration (FDA) has confirmed that is it has banned the import of more Ranbaxy drugs into the U. S. market.

The FDA banned the products produced at Ranbaxy Laboratories Ltd's Toansa, Punjab-based facility due to certain manufacturing violations.

The regulator said it prohibited certain pharmaceutical products from the Toansa facility to prevent poor quality quality products from reaching American consumers.

It said in a statement, "The FDA is committed to ensuring that the drugs American consumers receive - no matter where they are produced - meet quality standards and are safe and effective."

It is not the first time that the FDA has banned Ranbaxy drugs. Earlier, the American regulator banned allegedly substandard drugs from the company's other manufacturing facilities situated in Paonta Sahib, Mohali and Dewas, saying the products didn't comply with its good manufacturing practices.

Ranbaxy's majority owner, Japan-based Daiichi Sankyo Co Ltd, said it was confirming the situation with India-based Ranbaxy and would soon provide more details. Daiichi shares slipped 3.9 per cent to 1,827 yen in morning trade on Friday in Tokyo.

Tagged with